158 related articles for article (PubMed ID: 3539124)
1. Bactericidal effect of combinations of cephalosporins with tobramycin on clinical isolates of Escherichia coli, Klebsiella and Staphylococcus aureus.
Wagenvoort JH; Brus-Weijer L; Michel MF
Arzneimittelforschung; 1986 Sep; 36(9):1301-2. PubMed ID: 3539124
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergy of cefamandole-tobramycin combinations.
Valenti AJ; Siniscalchi AJ; Andriole VT
Yale J Biol Med; 1977; 50(2):177-82. PubMed ID: 331694
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli.
Nyhlén A; Ljungberg B; Nilsson-Ehle I; Odenholt I
Chemotherapy; 2002 May; 48(2):71-7. PubMed ID: 12011538
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial resistance: patterns and trends in the National University Hospital, Singapore (1989-1991).
Kumarasinghe G; Liew HY; Chow C
Malays J Pathol; 1992 Dec; 14(2):95-103. PubMed ID: 1304631
[TBL] [Abstract][Full Text] [Related]
5. Synergism and postantibiotic effect of tobramycin and Melaleuca alternifolia (tea tree) oil against Staphylococcus aureus and Escherichia coli.
D'Arrigo M; Ginestra G; Mandalari G; Furneri PM; Bisignano G
Phytomedicine; 2010 Apr; 17(5):317-22. PubMed ID: 19699074
[TBL] [Abstract][Full Text] [Related]
6. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
de Sá Del Fiol F; Rocha De Mattos Filho T; Groppo FC
Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
Verbist L
Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibility of some bacteria isolated from clinical samples to third-generation cephalosporins].
Willke A; Tural D
Mikrobiyol Bul; 1987 Oct; 21(4):279-83. PubMed ID: 3332704
[TBL] [Abstract][Full Text] [Related]
9. [Patterns of resistance of Staph aureus and gram-negative bacteria to aminoglycosides and cephalosporins].
Ruczkowska J; Dolna I
Wiad Lek; 1989 May; 42(9):579-83. PubMed ID: 2629327
[TBL] [Abstract][Full Text] [Related]
10. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.
Hanberger H; Burman LG; Cars O; Erlandsson M; Gill H; Nilsson LE; Nordlinder D; Walther SM;
Acta Anaesthesiol Scand; 2007 Aug; 51(7):937-41. PubMed ID: 17635399
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
12. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
Downs JT; Andriole VT
Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
[TBL] [Abstract][Full Text] [Related]
14. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
Corser CA; Day GJ; Humble MW
N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
[TBL] [Abstract][Full Text] [Related]
15. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
Duttaroy B; Mehta S
Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of cefoxitin, a new cephalosporin (author's transl)].
Shah PM; Zwischenbrugger H; Stille W
MMW Munch Med Wochenschr; 1976 Nov; 118(45):1469-72. PubMed ID: 825763
[TBL] [Abstract][Full Text] [Related]
18. In vitro bactericidal action of cephalosporins in different concentrations of serum.
Magliulo E; Ceccarelli G; Bianchi PP; Piantieri G; Cafarelli A
G Batteriol Virol Immunol; 1981; 74(1-6):39-47. PubMed ID: 6458527
[No Abstract] [Full Text] [Related]
19. Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon.
Kanj SS; Chedid M; Araj GF
J Med Liban; 2001; 49(1):13-7. PubMed ID: 11910959
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of several antimicrobial agents against selected clinical isolates.
Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ
S Afr Med J; 1990 Apr; 77(8):395-400. PubMed ID: 2109875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
